Breaking News, Collaborations & Alliances

ChromaTan and Landmark Bio Receive NIIMBL Grant 

Funds will help the companies create a platform for the manufacturing and characterization of AAV-based gene therapy vectors.

By: Rachel Klemovitch

Assistant Editor

ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support the development of a recombinant adeno-associated virus (AAV) production process as part of NIIMBL’s Viral Vector Manufacturing and Analytics Program. The NIIMBL award will enable ChromaTan and Landmark Bio to create a scalable and accessible platform for the manufacturing and characterization of AAV-based gene therapy vectors...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters